We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The results are coming from these locations;
Locations
United Kingdom
Belfast City Hospital Not yet recruiting
Belfast, United Kingdom, BT9 7AB
Contact: Lorcan McGarvey, MD FRCP
Queen Elizabeth Hospital, Recruiting
Birmingham, United Kingdom, B15 2GW
Contact: Davinder Dosanjh, DPhil, MRCP, FHEA
Bradford Royal Infirmary Recruiting
Bradford, United Kingdom, BD9 6RJ
Contact: Dinesh Saralaya, MBBS MD MRCP FRCP
Hull and East Yorkshire NHS Trust, Castle Hill Hospital, Recruiting
Hull, United Kingdom, HU16 5JQ
Contact: Michael Crooks, MBBS
Glenfield Hospital, Recruiting
Leicester, United Kingdom, LE3 9QP
Contact: Salman Siddiqui, Fellow of the Royal College of
Wythenshawe Hospital Recruiting
Manchester, United Kingdom, M23 9LT
Contact: Jaclyn Smith, MB ChB MRCP PhD FRCP
City Campus of Nottingham University Recruiting
Nottingham, United Kingdom, NG5 1PB
Contact: Tim Harrison, MBBS FRCP MD
John Radcliffe Hospital Recruiting
Oxford, United Kingdom, OX3 9DU
Contact: Najib Rahman, MB BCh MA
University Hospital Southampton Nhs Foundation Trust Recruiting
Southampton, United Kingdom, SO16 6YD
Contact: Tom Wilkinson t.wilkinson@soton.ac.uk
Principal Investigator: Tom Wilkinson
That's what makes this one a bit of a gamble Woodstock.. I'm hoping for fantastic results, save a lot of lives and big Pharma buys SNG for £500 million, too much to ask?
I am going to cry if the trial results of the treatment sng001 are good.
smaller=smaller portion
Chrishar - I'm well aware this isn't just a COVID stock. Since I was one of the very few people invested in here before this year :p
"According to SS our broker forecast is £1.20 pre results... I should hope positive COPD results lead to more than your supposed range of 50-100p Rich."
Yes, they estimate the risked value at £1.20 now and £3.60 upon success.
However if you look at the breakdowns you'll see the COPD portion is a smaller of that £1.20/£3.60.
I actually think they've been conservative on the COPD valuation, and it may well be worth more than the broker forecast, but their risked value of SNG001 in COPD currently is £41m (27p per share) and it doesn't breakdown the CoS for each but if it's equal than their valuation on success is 27p*3=81p.
So their forecast for success on COPD is pretty much in the middle of the range I said for COPD success (although I do think it has potential to be more with a fair wind).
We have to remember that for many who are infected the scarring on lungs could last some time if not for life. SNG001 will be the perfect drug to use for these people during flu and colds etc like COPD patients.
Winner winner chicken dinner with Synairgen, all people need is patience.
The results will be the same as the astrazeneca trial: AZD9412 is SNG 001
"Treatment with AZD9412 switched on antiviral responses in the lungs, improved morning peak flow (a measure of lung function), and was well tolerated
· The study however, did not meet AstraZeneca's predefined criteria for progression, and they have elected to return the rights to AZD9412 to Synairgen.. Treatment with inhaled interferon beta did however switch on the lungs' antiviral defences (as measured by blood levels of the antiviral biomarker CXCL10), have a beneficial effect on lung function (Morning Peak Expiratory Flow: difference of 19.7 litres per minute average over the first 7 days of treatment (p=0.01)), and was well tolerated. Effects on biomarkers, lung function and the good tolerability profile "
Price based on positive results? £1.80!!!!! and the booby prize is a blankety blank cheque book and pen ;-)
According to SS our broker forecast is £1.20 pre results... I should hope positive COPD results lead to more than your supposed range of 50-100p Rich.
As has been said on here hundreds of times, this is NOT a covid stock. COPD is the bigger market...
Impossible to know.
Good results on COPD could easily be 50-100p. Good results on COVID too and it could be many multiples of that. Just going to have to wait and see.
It's not hard to imagine the media circus if they show good results in treating COVID patients in a serious double-blind placebo controlled trial. America bought the entire stocks of remdesivir based on mild/moderate improvements in a small subset of patients at a particular stage of the disease!
Will probably drop
1 million pound a share
Results are due this month and it’s likely to be positive imho. What SP do we expect on positive results?